Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy.

Nancy BroosLeiah J BrigithaAnnemieke SchuurhofHeike Röckmann-HelmbachWim J E TissingRob PietersInge M van der SluisMarike B Stadermann

Published in: EJC paediatric oncology (2022)

Children with a PEG-asparaginase allergy can be safely vaccinated against COVID-19 with mRNA vaccines containing PEG irrespective of IgG/IgM antibodies to PEG-asparaginase. Routine skin prick testing in patients with PEG-asparaginase allergy does not seem to be of added value.

Keyphrases

drug delivery
coronavirus disease
sars cov
atopic dermatitis
emergency department
young adults
infectious diseases
binding protein